Indeed, such tests guide clinical decisions in a similar fashion to trastuzumab administration on the basis of HER2 positivity or antiestrogen treatment on the basis of estrogen receptor positivity in breast cancer. This evidence concerns the gene ERBB2 and breast cancer.